RE:RE:RE:RE:7%"I defended CZO and finally just got to the point where I realized nothing was coming from it."
CZO stronger than ever?
1) $11 million cash with no debt and $5.14 million in inventory on standby.
2) The deal with Symrise was recently extended. They are additionally developing a preservative free, powder beta glucan for their portfolio now.
3) Avenanthramide pill has been successfully developed and approved for a Phase I/IIa clinical trial under the Montreal Heart Institute. Recruitment/enrollment expected to begin in the next 1 1/2 months
4) Construction of a 5X scale-up of the PGX pilot plant is expected to in the next 3 months with commissioning expected in Q1 2024. A 10X scale-up of the pilot plant is expected by Q3 2024.
5) The prototype PGX-OBG/CoQ10 was taken to industry and based on feedback PGX-YBG, PGX-Alginate, PGX-Alginate-YBG/CoQ10 have been developed to best address industry needs. Bioavailability results at the University of Alberta blew away the industry gold standard.
6) Gilles has noted talks with serius companies have been taking place concerning PGX licensing with serious companies. The companies understand the significance of bioavailability as a unique selling point. The CoQ10 market was noted to be $4 billion.
7) PGX-YBG is 5X more stimulative of dectin-1 giving it a potential competitive advantage in the immune booster market.
8) Avenanthramide and beta glucan have been demonstrated in the established model for wound healing with the Angiogenesis Foundation. Additional studies are ongoing. Dr. Li said it was a potential Intel Inside type product with numerous potential applications.
9) PGX-YBG is undergoing toxicology studies ahead of a potential Phase I clinical decision for fibrosis. Dr. Kolb said that if results in mice are replicated in humans it could have a profound effect on the treatment landscape. He is an internationally recognized scientist in the field.
10) Strategic initiatives such as new revenue opportunities and a NASDAQ upliting is being explored to add to and unlock value. News release: "Further, over the past quarter we remained very active with our activities related to strategic corporate initiatives."
June 6, 2023 AGM Quotes:
Ronnie Miller, "With our sound core business and multi-product pipeline these are indeed exciting times at your company...While we are always facing some challenges I do believe we are poised for growth which I'm convinced will bring Ceapro and all of its stakeholders excellent results as we move forward".
Gilles, "I echo Ronnie's comments regarding the fact that we have built a very solid company that is poised for growth".
Gilles, "So at the end of the day we are really, really we are poised for growth. We have a fantastic team in place. We have a healthy balance sheet We have great financials. We have built a profitable company despite a little bit of a glitch for the first half of this year; but we are confident that the re-ordering pattern in our base business will get back to normal. It's a question...our base business is not in danger. It's a question of timing. So we are very confident that we will experience another solid year and beyond. We are poised for success and we will look for different ways to unlock value."
6)
Discussion